Drug survival of adalimumab is superior to infliximab in pediatric patients with hidradenitis suppurativa
Publication
, Journal Article
Guo, R; Jaleel, T; Stein, AB; Garza-Mayers, AC; Kroshinsky, D
Published in: Journal of the American Academy of Dermatology
January 1, 2025
Duke Scholars
Published In
Journal of the American Academy of Dermatology
DOI
EISSN
1097-6787
ISSN
0190-9622
Publication Date
January 1, 2025
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Guo, R., Jaleel, T., Stein, A. B., Garza-Mayers, A. C., & Kroshinsky, D. (2025). Drug survival of adalimumab is superior to infliximab in pediatric patients with hidradenitis suppurativa. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.10.071
Guo, R., T. Jaleel, A. B. Stein, A. C. Garza-Mayers, and D. Kroshinsky. “Drug survival of adalimumab is superior to infliximab in pediatric patients with hidradenitis suppurativa.” Journal of the American Academy of Dermatology, January 1, 2025. https://doi.org/10.1016/j.jaad.2025.10.071.
Guo R, Jaleel T, Stein AB, Garza-Mayers AC, Kroshinsky D. Drug survival of adalimumab is superior to infliximab in pediatric patients with hidradenitis suppurativa. Journal of the American Academy of Dermatology. 2025 Jan 1;
Guo, R., et al. “Drug survival of adalimumab is superior to infliximab in pediatric patients with hidradenitis suppurativa.” Journal of the American Academy of Dermatology, Jan. 2025. Scopus, doi:10.1016/j.jaad.2025.10.071.
Guo R, Jaleel T, Stein AB, Garza-Mayers AC, Kroshinsky D. Drug survival of adalimumab is superior to infliximab in pediatric patients with hidradenitis suppurativa. Journal of the American Academy of Dermatology. 2025 Jan 1;
Published In
Journal of the American Academy of Dermatology
DOI
EISSN
1097-6787
ISSN
0190-9622
Publication Date
January 1, 2025
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1103 Clinical Sciences